

## DAFTAR PUSTAKA

- Adams, M.D., Goglin, K., Molyneaux, N., Hujer, K.M., Lavender, H., Jamison, J.J., et al., 2008. Comparative genome sequence analysis of multidrug-resistant *Acinetobacter baumannii*. *J. Bacteriol.* 190: 8053–8064. doi:10.1128/JB.00834-08
- Adams, M.D., Nickel, G.C., Bajaksouzian, S., Lavender, H., Murthy, A.R., Jacobs, M.R., et al., 2009. Resistance to colistin in *Acinetobacter baumannii* associated with mutations in the PmrAB two-component system. *Antimicrob. Agents Chemother.* 53: 3628–3634. doi:10.1128/AAC.00284-09
- Afhami, S., Borumand, M.A., Bazzaz, N.E., Saffar, H., Hadadi, A., & Jafary, M., 2021. Antimicrobial resistance pattern of *Acinetobacter*; a multicenter study, comparing European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI); evaluation of susceptibility testing me 7: 5–9. doi:10.34172/ipp.2021.04
- Afzal-Shah, M., & Livermore, D.M., 1998. Worldwide emergence of carbapenem-resistant *Acinetobacter* spp. [5]. *J. Antimicrob. Chemother.* doi:10.1093/jac/41.5.576
- Al-Zahrani, I.A., 2018a. Routine detection of carbapenem-resistant gram-negative bacilli in clinical laboratories.: A review of current challenges. *Saudi Med. J.* doi:10.15537/smj.2018.9.22840
- Albrecht, M.A., Griffith, M.E., Murray, C.K., Chung, K.K., Horvath, E.E., Ward, J.A., et al., 2006. Impact of *Acinetobacter* Infection on the Mortality of Burn Patients. *J. Am. Coll. Surg.* 203: 546–550. doi:10.1016/j.jamcollsurg.2006.06.013
- Apisarnthanarak, A., Buppunharun, W., Tiengrim, S., Sawanpanyalert, P., & Aswapokee, N., 2009. An overview of antimicrobial susceptibility patterns for gram-negative bacteria from the National Antimicrobial Resistance Surveillance Thailand (NARST) program from 2000 to 2005. *J. Med. Assoc. Thai.* 92 Suppl 4.
- Ayobami, O., Willrich, N., Harder, T., Okeke, I.N., Eckmanns, T., & Markwart, R., 2019. The incidence and prevalence of hospital-acquired (carbapenem-resistant) *Acinetobacter baumannii* in Europe, Eastern Mediterranean and Africa: a systematic review and meta-analysis. *Emerg. Microbes Infect.* 8: 1747–1759. doi:10.1080/22221751.2019.1698273
- Baran, G., Erbay, A., Bodur, H., Öngürü, P., Akinci, E., Balaban, N., et al., 2008. Risk factors for nosocomial imipenem-resistant *Acinetobacter baumannii* infections. *Int. J. Infect. Dis.* 12: 16–21. doi:10.1016/j.ijid.2007.03.005
- Bayuga, S., Zeana, C., Sahni, J., Della-Latta, P., El-Sadr, W., & Larson, E., 2002. Prevalence and antimicrobial patterns of *Acinetobacter baumannii* on hands and nares of hospital personnel and patients: The iceberg phenomenon again. *Hear. Lung J. Acute Crit. Care* 31: 382–390. doi:10.1067/mhl.2002.126103
- Beceiro, A., Llobet, E., Aranda, J., Bengoechea, J.A., Doumith, M., Hornsey, M., et al., 2011. Phosphoethanolamine modification of lipid A in colistin-resistant

- variants of *Acinetobacter baumannii* mediated by the pmrAB two-component regulatory system. *Antimicrob. Agents Chemother.* 55: 3370–3379. doi:10.1128/AAC.00079-11
- Bergogne-Bérézin, E., & Towner, K.J., 1996. *Acinetobacter spp.* as nosocomial pathogens: Microbiological, clinical, and epidemiological features. *Clin. Microbiol. Rev.* 9: 148–165. doi:10.1128/cmr.9.2.148-165.1996
- Boinett, C.J., Cain, A.K., Hawkey, J., Hoang, N.T. Do, Khanh, N.N.T., Thanh, D.P., et al., 2019. Clinical and laboratory-induced colistin-resistance mechanisms in *Acinetobacter baumannii*. *Microb. Genomics* 5. doi:10.1099/mgen.0.000246
- Brown, S., & Amyes, S., 2006. OXA  $\beta$ -lactamases in *Acinetobacter*: The story so far. *J. Antimicrob. Chemother.* doi:10.1093/jac/dki425
- Buxton, A.E., Anderson, R.L., Werdegar, D., & Atlas, E., 1978. Nosocomial respiratory tract infection and colonization with *Acinetobacter calcoaceticus*. Epidemiologic characteristics. *Am. J. Med.* 65: 507–513. doi:10.1016/0002-9343(78)90777-5
- C Reygaert, W., 2018. An overview of the antimicrobial resistance mechanisms of bacteria. *AIMS Microbiol.* 4: 482–501. doi:10.3934/microbiol.2018.3.482
- Cai, B., Echols, R., Magee, G., Arjona Ferreira, J.C., Morgan, G., Ariyasu, M., et al., 2017. Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by *Acinetobacter baumannii* and *Pseudomonas aeruginosa*. *Open Forum Infect. Dis.* 4: 1–7. doi:10.1093/ofid/ofx176
- Chen, M.Z., Hsueh, P.R., Lee, L.N., Yu, C.J., Yang, P.C., & Luh, K.T., 2001. Severe community-acquired pneumonia due to *Acinetobacter baumannii*. *Chest* 120: 1072–1077. doi:10.1378/chest.120.4.1072
- Chen, Y.H., Chiueh, C.C., & Lee, Y.J., 2014. Risk Factors of Carbapenem-resistant *Acinetobacter baumannii* Infection among Hospitalized Patients. *J. Exp. Clin. Med.* 6: 143–146. doi:10.1016/j.jecm.2014.06.003
- Chin, C.Y., Tipton, K.A., Farokhyfar, M., Burd, E.M., Weiss, D.S., & Rather, P.N., 2018. A high-frequency phenotypic switch links bacterial virulence and environmental survival in *Acinetobacter baumannii*. *Nat. Microbiol.* 3: 563–569. doi:10.1038/s41564-018-0151-5
- Choi, C.H., Hyun, S.H., Lee, J.Y., Lee, J.S., Lee, Y.S., Kim, S.A., et al., 2008a. *Acinetobacter baumannii* outer membrane protein A targets the nucleus and induces cytotoxicity. *Cell. Microbiol.* 10: 309–319. doi:10.1111/j.1462-5822.2007.01041.x
- Choi, C.H., Hyun, S.H., Lee, J.Y., Lee, J.S., Lee, Y.S., Kim, S.A., et al., 2008b. *Acinetobacter baumannii* outer membrane protein A targets the nucleus and induces cytotoxicity. *Cell. Microbiol.* 10: 309–319. doi:10.1111/j.1462-5822.2007.01041.x
- Chopra, T., Marchaim, D., Awali, R.A., Krishna, A., Johnson, P., Tansek, R., et al., 2013. Epidemiology of bloodstream infections caused by *Acinetobacter baumannii* and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes. *Antimicrob. Agents Chemother.* 57: 6270–6275.

doi:10.1128/AAC.01520-13

- Craven, D.E., Lei, Y., Ruthazer, R., Sarwar, A., & Hudcova, J., 2013. Incidence and outcomes of ventilator-associated tracheobronchitis and pneumonia. *Am. J. Med.* 126: 542–549. doi:10.1016/j.amjmed.2012.12.012
- Dahdouh, E., Hajjar, M., Suarez, M., & Daoud, Z., 2016. *Acinetobacter baumannii* isolated from lebanese patients: Phenotypes and genotypes of resistance, clonality, and determinants of pathogenicity. *Front. Cell. Infect. Microbiol.* 6. doi:10.3389/fcimb.2016.00163
- Dahesih, D., Dewi, Y.P., Sugainli, A.K., & Parwati, I., 2019. Surveilans Bakteri Resistan Multi obat dan Kepekaannya Terhadap Aantibiotik di Rumah Sakit Indonesia Tahun 2018.
- Davandeh, I., Eraç, B., & Aydemir, S.Ş., 2017. Investigation of class-d beta-lactamases causing carbapenem resistance in clinical *Acinetobacter baumannii* isolates. *Turkish J. Med. Sci.* 47: 1661–1666. doi:10.3906/sag-1607-91
- Dettoni, M., Piana, A., Deriu, M.G., Curto, A. Lo, Cossu, A., Musumeci, R., et al., 2014. Outbreak of multidrug-resistant *Acinetobacter baumannii* in an intensive care unit. *New Microbiol.* 37: 185–191.
- Djordjevic, Z.M., Folic, M.M., Folic, N.D., Gajovic, N., Gajovic, O., & Jankovic, S.M., 2016. Risk factors for hospital infections caused by carbapenem-resistant *Acinetobacter baumannii*. *J. Infect. Dev. Ctries.* 10: 1073–1080. doi:10.3855/jidc.8231
- Du, D., Wang-Kan, X., Neuberger, A., van Veen, H.W., Pos, K.M., Piddock, L.J.V., et al., 2018a. Multidrug efflux pumps: structure, function and regulation. *Nat. Rev. Microbiol.* doi:10.1038/s41579-018-0048-6
- Du, D., Wang-Kan, X., Neuberger, A., van Veen, H.W., Pos, K.M., Piddock, L.J.V., et al., 2018b. Erratum to: Multidrug efflux pumps: structure, function and regulation (Nature Reviews Microbiology, (2018), 16, 9, (523-539), 10.1038/s41579-018-0048-6). *Nat. Rev. Microbiol.* doi:10.1038/s41579-018-0060-x
- Eijkelkamp, B.A., Stroehner, U.H., Hassan, K.A., Elbourne, L.D.H., Paulsen, I.T., & Brown, M.H., 2013. H-NS Plays a role in expression of *Acinetobacter baumannii* virulence features. *Infect. Immun.* 81: 2574–2583. doi:10.1128/IAI.00065-13
- Erridge, C., Moncayo-Nieto, O.L., Morgan, R., Young, M., & Poxton, I.R., 2007. *Acinetobacter baumannii* lipopolysaccharides are potent stimulators of human monocyte activation via Toll-like receptor 4 signalling. *J. Med. Microbiol.* 56: 165–171. doi:10.1099/jmm.0.46823-0
- Evans, B.A., & Amyes, S.G.B., 2014. OXA  $\beta$ -lactamases. *Clin. Microbiol. Rev.* 27: 241–263. doi:10.1128/CMR.00117-13
- Fiester, S.E., Nwugo, C.C., Penwell, W.F., Neary, J.M., Beckett, A.C., Arivett, B.A., et al., 2015. Role of the carboxy terminus of SecA in iron acquisition, protein translocation, and virulence of the bacterial pathogen *Acinetobacter baumannii*. *Infect. Immun.* 83: 1354–1365. doi:10.1128/IAI.02925-14
- Fournier, P.E., & Richet, H., 2006. The epidemiology and control of *Acinetobacter baumannii* in health care facilities. *Clin. Infect. Dis.* 42: 692–699.

doi:10.1086/500202

- Fournier, P.E., Vallenet, D., Barbe, V., Audic, S., Ogata, H., Poirel, L., et al., 2006. Comparative genomics of multidrug resistance in *Acinetobacter baumannii*. *PLoS Genet.* 2: 62–72. doi:10.1371/journal.pgen.0020007
- Gaddy, J.A., Actis, L.A., Arivett, B.A., McConnell, M.J., Rafael, L.R., & Pachón, J., 2012. Role of Acinetobactin-mediated iron acquisition functions in the interaction of *Acinetobacter baumannii* strain ATCC 19606T with human lung epithelial cells, *Galleria mellonella* caterpillars, and mice. *Infect. Immun.* 80: 1015–1024. doi:10.1128/IAI.06279-11
- García-Garmendia, J.L., Garnacho-Montero, J., Ortiz-Leyba, C., Jiménez-Jiménez, F.J., & Gili-Miner, M., 1999. Risk factors for *Acinetobacter baumannii* (AB) nosocomial bacteremia in critically ill patients: A cohort study. *Crit. Care Med.* 27. doi:10.1097/00003246-199901001-00348
- Garnacho-Montero, J., Ortiz-Leyba, C., Fernández-Hinojosa, E., Aldabó-Pallás, T., Cayuela, A., Marquez-Vácaro, J.A., et al., 2005. *Acinetobacter baumannii* ventilator-associated pneumonia: Epidemiological and clinical findings. *Intensive Care Med.* 31: 649–655. doi:10.1007/s00134-005-2598-0
- Go, E.S., Urban, C., Burns, J., Mariano, N., Mosinka-Snipas, K., Rahal, J.J., et al., 1994. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. *Lancet* 344: 1329–1332. doi:10.1016/S0140-6736(94)90694-7
- Guan, X., He, L., Hu, B., Hu, J., Huang, X., Lai, G., et al., 2016. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: A Chinese consensus statement. *Clin. Microbiol. Infect.* 22: S15–S25. doi:10.1016/j.cmi.2015.11.004
- Guo, N., Xue, W., Tang, D., Ding, J., & Zhao, B., 2016a. Risk factors and outcomes of hospitalized patients with blood infections caused by multidrug-resistant *Acinetobacter baumannii* complex in a hospital of Northern China. *Am. J. Infect. Control* 44: e37–e39. doi:10.1016/j.ajic.2015.11.019
- Guo, N., Xue, W., Tang, D., Ding, J., & Zhao, B., 2016b. Risk factors and outcomes of hospitalized patients with blood infections caused by multidrug-resistant *Acinetobacter baumannii* complex in a hospital of Northern China. *Am. J. Infect. Control* 44: e37–e39. doi:10.1016/j.ajic.2015.11.019
- Guo, N., Xue, W., Tang, D., Ding, J., & Zhao, B., 2016c. Risk factors and outcomes of hospitalized patients with blood infections caused by multidrug-resistant *Acinetobacter baumannii* complex in a hospital of Northern China. *Am. J. Infect. Control* 44: e37–e39. doi:10.1016/j.ajic.2015.11.019
- Henig, O., Weber, G., Hoshen, M.B., Paul, M., German, L., & Neuberger, A., 2015. Risk factors for and impact of carbapenem-resistant *Acinetobacter baumannii* colonization and infection: matched case – control study. doi:10.1007/s10096-015-2452-4
- Huang, L., Chen, T.L., Lee, Y.T., Lee, M.H., Kuo, S.C., Yu, K.W., et al., 2014. Risk factors for imipenem-nonsusceptible *Acinetobacter* nosocomialis bloodstream



- infection. *J. Microbiol. Immunol. Infect.* 47: 311–317. doi:10.1016/j.jmii.2013.02.002
- Huang, S.T., Chiang, M.C., Kuo, S.C., Lee, Y.T., Chiang, T.H., Yang, S.P., et al., 2012. Risk factors and clinical outcomes of patients with carbapenem-resistant *Acinetobacter baumannii* bacteremia. *J. Microbiol. Immunol. Infect.* 45: 356–362. doi:10.1016/j.jmii.2011.12.009
- Iwashkiw, J.A., Seper, A., Weber, B.S., Scott, N.E., Vinogradov, E., Stratilo, C., et al., 2012. Identification of a General O-linked Protein Glycosylation System in *Acinetobacter baumannii* and Its Role in Virulence and Biofilm Formation. *PLoS Pathog.* 8: e1002758. doi:10.1371/journal.ppat.1002758
- Iyer, R., Moussa, S.H., Durand-Réville, T.F., Tommasi, R., & Miller, A., 2018. *Acinetobacter baumannii* OmpA Is a Selective Antibiotic Permeant Porin. *ACS Infect. Dis.* 4: 373–381. doi:10.1021/acsinfecdis.7b00168
- Jamal, S., Al Atrouni, A., Rafei, R., Dabboussi, F., Hamze, M., & Osman, M., 2018a. Molecular mechanisms of antimicrobial resistance in *Acinetobacter baumannii*, with a special focus on its epidemiology in Lebanon. *J. Glob. Antimicrob. Resist.* doi:10.1016/j.jgar.2018.05.022
- Jones, C.L., Clancy, M., Honnold, C., Singh, S., Snesrud, E., Onmus-Leone, F., et al., 2015. Fatal Outbreak of an Emerging Clone of Extensively Drug-Resistant *Acinetobacter baumannii* with Enhanced Virulence. *Clin. Infect. Dis.* 61: 145–154. doi:10.1093/cid/civ225
- Jung, J.Y., Park, M.S., Kim, S.E., Park, B.H., Son, J.Y., Kim, E.Y., et al., 2010. Risk factors for multi-drug resistant *Acinetobacter baumannii* bacteremia in patients with colonization in the intensive care unit. *BMC Infect. Dis.* 10. doi:10.1186/1471-2334-10-228
- Kandemir, Ö., Akbay, E., Şahin, E., Milcan, A., & Gen, R., 2007. Risk factors for infection of the diabetic foot with multi-antibiotic resistant microorganisms. *J. Infect.* 54: 439–445. doi:10.1016/j.jinf.2006.08.013
- Kim, S.Y., Jung, J.Y., Kang, Y.A., Lim, J.E., Kim, E.Y., Lee, S.K., et al., 2012. Risk factors for occurrence and 30-day mortality for carbapenem-resistant *Acinetobacter baumannii* bacteremia in an intensive care unit. *J. Korean Med. Sci.* 27: 939–947. doi:10.3346/jkms.2012.27.8.939
- Kofteridis, D.P., Valachis, A., Dimopoulou, D., Maraki, S., Christidou, A., Mantadakis, E., et al., 2014. Risk factors for carbapenem-resistant *Klebsiella pneumoniae* infection/colonization: A case-case-control study. *J. Infect. Chemother.* 20: 293–297. doi:10.1016/j.jiac.2013.11.007
- Kruse, E.B., Aurbach, U., & Wisplinghoff, H., 2013. Carbapenem-resistant enterobacteriaceae: Laboratory detection and infection control practices. *Curr. Infect. Dis. Rep.* 15: 549–558. doi:10.1007/s11908-013-0373-x
- Kumar, A., Randhawa, V.S., Nirupam, N., Rai, Y., & Saili, A., 2014. Risk factors for carbapenem-resistant *Acinetobacter baumannii* blood stream infections in a neonatal intensive care unit, Delhi, India. *J. Infect. Dev. Ctries.* 8: 1049–1054. doi:10.3855/jidc.4248



- Kuo, H.-Y., Chao, H.-H., Liao, P.-C., Hsu, L., Chang, K.-C., Tung, C.-H., et al., 2017. Functional Characterization of *Acinetobacter baumannii* Lacking the RNA Chaperone Hfq. *Front. Microbiol.* 8: 2068. doi:10.3389/fmicb.2017.02068
- Labaste, F., Grossac, J., Bounes, F.V., Conil, J.M., Ruiz, S., Seguin, T., et al., 2019a. Risk factors for acquisition of carbapenem-resistance during treatment with carbapenem in the intensive care unit: a prospective study. *Eur. J. Clin. Microbiol. Infect. Dis.* 38: 2077–2085. doi:10.1007/s10096-019-03644-6
- Le Hello, S., Falcot, V., Lacassin, F., Mikulski, M., & Baumann, F., 2010. Risk factors for carbapenem-resistant *Acinetobacter baumannii* infections at a tertiary care hospital in New Caledonia, South Pacific. *Scand. J. Infect. Dis.* 42: 821–826. doi:10.3109/00365548.2010.496087
- Lee, C.R., Lee, J.H., Park, M., Park, K.S., Bae, I.K., Kim, Y.B., et al., 2017. Biology of *Acinetobacter baumannii*: Pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. *Front. Cell. Infect. Microbiol.* 7. doi:10.3389/fcimb.2017.00055
- Li, J., Nation, R.L., Milne, R.W., Turnidge, J.D., & Coulthard, K., 2005. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. *Int. J. Antimicrob. Agents.* doi:10.1016/j.ijantimicag.2004.10.001
- Lin, M.Y., Ray, M.J., Rezny, S., Runningdeer, E., Weinstein, R.A., & Trick, W.E., 2019. Predicting carbapenem-resistant enterobacteriaceae carriage at the time of admission using a statewide hospital discharge database. *Open Forum Infect. Dis.* 6. doi:10.1093/ofid/ofz483
- Liu, Q., Li, Wenzhang, Du, X., Li, Weijing, Zhong, T., Tang, Y., et al., 2015. Risk and prognostic factors for multidrug-resistant *Acinetobacter baumannii* complex bacteremia: A retrospective study in a tertiary hospital of West China. *PLoS One* 10. doi:10.1371/journal.pone.0130701
- Mahamat, A., Bertrand, X., Moreau, B., Hommel, D., Couppie, P., Simonnet, C., et al., 2016. Clinical epidemiology and resistance mechanisms of carbapenem-resistant *Acinetobacter baumannii*, French Guiana, 2008–2014. *Int. J. Antimicrob. Agents* 48: 51–55. doi:10.1016/j.ijantimicag.2016.03.006
- Mahgoub, S., Ahmed, J., & Glatt, A.E., 2002. Underlying characteristics of patients harboring highly resistant *Acinetobacter baumannii*. *Am. J. Infect. Control* 30: 386–390. doi:10.1067/mic.2002.122648
- Manchanda, V., Sinha, S., & Singh, N., 2010. Multidrug resistant *Acinetobacter*. *J. Glob. Infect. Dis.* 2: 291. doi:10.4103/0974-777x.68538
- Marchand, I., Damier-Piolle, L., Courvalin, P., & Lambert, T., 2004. Expression of the RND-type efflux pump AdeABC in *Acinetobacter baumannii* is regulated by the AdeRS two-component system. *Antimicrob. Agents Chemother.* 48: 3298–3304. doi:10.1128/AAC.48.9.3298-3304.2004
- Martín-Aspas, A., Guerrero-Sánchez, F.M., García-Colchero, F., Rodríguez-Roca, S., & Girón-González, J.A., 2018. Differential characteristics of *Acinetobacter baumannii* colonization and infection: Risk factors, clinical picture, and mortality. *Infect. Drug Resist.* 11: 861–872. doi:10.2147/IDR.S163944



- Meletis, G., 2016a. Carbapenem resistance: overview of the problem and future perspectives. *Ther. Adv. Infect. Dis.* 3: 15–21. doi:10.1177/2049936115621709
- Meletis, G., 2016b. Carbapenem resistance: overview of the problem and future perspectives. *Ther. Adv. Infect. Dis.* 3: 15–21. doi:10.1177/2049936115621709
- Mesiano, E.R.A.B., & Merchán-Hamann, E., 2007. Bloodstream infections among patients using central venous catheters in intensive care units. *Rev. Lat. Am. Enfermagem* 15: 453–459. doi:10.1590/s0104-11692007000300014
- Mody, L., Gibson, K.E., Horcher, A., Prenovost, K., McNamara, S.E., Foxman, B., et al., 2015. Prevalence of and risk factors for multidrug-resistant *Acinetobacter baumannii* colonization among high-risk nursing home residents. *Infect. Control Hosp. Epidemiol.* 36: 1155–1162. doi:10.1017/ice.2015.143
- Moffatt, J.H., Harper, M., Harrison, P., Hale, J.D.F., Vinogradov, E., Seemann, T., et al., 2010. Colistin resistance in *Acinetobacter baumannii* is mediated by complete loss of lipopolysaccharide production. *Antimicrob. Agents Chemother.* 54: 4971–4977. doi:10.1128/AAC.00834-10
- Moghnieh, R., Tamim, H., Jadayel, M., Abdallah, D., Al-Kassem, R., Kadiri, H., et al., 2020. The effect of temporary closure and enhanced terminal disinfection using aerosolized hydrogen peroxide of an open-bay intensive care unit on the acquisition of extensively drug-resistant *Acinetobacter baumannii*. *Antimicrob. Resist. Infect. Control* 9. doi:10.1186/s13756-020-00772-z
- Montefour, K., Frieden, J., Hurst, S., Helmich, C., Headley, D., Martin, M., et al., 2008. *Acinetobacter baumannii*: An emerging multidrug-resistant pathogen in critical care. *Crit. Care Nurse* 28: 15–25. doi:10.4037/ccn2008.28.1.15
- Moon, D.C., Choi, C.H., Lee, J.H., Choi, C.W., Kim, H.Y., Park, J.S., et al., 2012. *Acinetobacter baumannii* outer membrane protein a modulates the biogenesis of outer membrane vesicles. *J. Microbiol.* 50: 155–160. doi:10.1007/s12275-012-1589-4
- Morris, F.C., Dexter, C., Kostoulias, X., Uddin, M.I., & Peleg, A.Y., 2019. The Mechanisms of Disease Caused by *Acinetobacter baumannii*. *Front. Microbiol.* 10: 1601. doi:10.3389/fmicb.2019.01601
- Mussi, M.A., Limansky, A.S., & Viale, A.M., 2005. Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of *Acinetobacter baumannii*: Natural insertional inactivation of a gene encoding a member of a novel family of  $\beta$ -barrel outer membrane proteins. *Antimicrob. Agents Chemother.* 49: 1432–1440. doi:10.1128/AAC.49.4.1432-1440.2005
- Nakwan, Narongsak, Wannaro, J., Nakwan, Narongwit, Patungkalo, W., & Choekhaibulkit, K., 2012. Clinical features, risk factors, and outcome of carbapenem-resistant *Acinetobacter baumannii* bacteremia in a Thai neonatal intensive care unit. *Asian Biomed.* 6: 473–479. doi:10.5372/1905-7415.0603.079
- Nemec, A., Dijkshoorn, L., & Van Der Reijden, T.J.K., 2004a. Long-term predominance of two pan-European clones among multi-resistant *Acinetobacter baumannii* strains in the Czech Republic. *J. Med. Microbiol.* 53: 147–153. doi:10.1099/jmm.0.05445-0

- Nemec, A., Dolzani, L., Brisse, S., Van Den Broek, P., & Dijkshoorn, L., 2004b. Diversity of aminoglycoside-resistance genes and their association with class 1 integrons among strains of pan-European *Acinetobacter baumannii* clones. *J. Med. Microbiol.* 53: 1233–1240. doi:10.1099/jmm.0.45716-0
- Ng, T.M., Teng, C.B., Lye, D.C., & Apisarnthanarak, A., 2014. A Multicenter Case-Case Control Study for Risk Factors and Outcomes of Extensively Drug-Resistant *Acinetobacter baumannii* Bacteremia. *Infect. Control Hosp. Epidemiol.* 35: 49–55. doi:10.1086/674387
- Nhu, N.T.K., Lan, N.P.H., Campbell, J.I., Parry, C.M., Thompson, C., Tuyen, H.T., et al., 2014. Emergence of carbapenem-resistant *Acinetobacter baumannii* as the major cause of ventilator-associated pneumonia in intensive care unit patients at an infectious disease hospital in southern Vietnam. *J. Med. Microbiol.* 63: 1386–1394. doi:10.1099/jmm.0.076646-0
- Özgür, E.S., Horasan, E.S., Karaca, K., Ersöz, G., Nayci Atiş, S., & Kaya, A., 2014. Ventilator-associated pneumonia due to extensive drug-resistant *Acinetobacter baumannii*: Risk factors, clinical features, and outcomes. *Am. J. Infect. Control* 42: 206–208. doi:10.1016/j.ajic.2013.09.003
- Peleg, A.Y., Seifert, H., & Paterson, D.L., 2008. *Acinetobacter baumannii*: Emergence of a successful pathogen. *Clin. Microbiol. Rev.* doi:10.1128/CMR.00058-07
- Playford, E.G., Craig, J.C., & Iredell, J.R., 2007. Carbapenem-resistant *Acinetobacter baumannii* in intensive care unit patients: risk factors for acquisition, infection and their consequences. *J. Hosp. Infect.* 65: 204–211. doi:10.1016/j.jhin.2006.11.010
- Pogue, J.M., Kanakamedala, H., Zhou, Y., & Cai, B., 2019. 551. Burden of Illness in Carbapenem-Resistant *Acinetobacter baumannii* Infections in US Hospitals (2014 to 2018). *Open Forum Infect. Dis.* 6: S262–S262. doi:10.1093/ofid/ofz360.620
- Poirel, L., Héritier, C., Tolün, V., & Nordmann, P., 2004. Emergence of Oxacillinase-Mediated Resistance to Imipenem in *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* 48: 15–22. doi:10.1128/AAC.48.1.15-22.2004
- Powers, M.J., & Trent, M.S., 2018. Expanding the paradigm for the outer membrane: *Acinetobacter baumannii* in the absence of endotoxin. *Mol. Microbiol.* doi:10.1111/mmi.13872
- Primaningtyas, W., Pamungkasari, E.P., & -, S., 2017. Factors Causing *Acinetobacter baumannii* Resistance to Carbapenem Antibiotics in Patients with Healthcare Associated Infection (HCAI) at Dr. Moewardi Hospital, Surakarta. *Indones. J. Med.* 02: 125–138. doi:10.26911/theijmed.2017.02.02.07
- Rafei, R., Pailhoriès, H., Hamze, M., Eveillard, M., Mallat, H., Dabboussi, F., et al., 2015. Molecular epidemiology of *Acinetobacter baumannii* in different hospitals in Tripoli, Lebanon using bla OXA-51-like sequence based typing. *BMC Microbiol.* 15: 1–7. doi:10.1186/s12866-015-0441-5
- Saharman, Y.R., Karuniawati, A., Sedono, R., Aditjaningsih, D., Goessens, W.H.F., Klaassen, C.H.W., et al., 2020. Clinical impact of endemic NDM-producing *Klebsiella pneumoniae* in intensive care units of the national referral hospital in Jakarta, Indonesia. *Antimicrob. Resist. Infect. Control* 9. doi:10.1186/s13756-020-



00716-7

- Saharman, Y.R., Karuniawati, A., Sedono, R., Aditiansih, D., Sudarmono, P., Goessens, W.H.F., et al., 2018. Endemic carbapenem-nonsusceptible *Acinetobacter baumannii*-calcoaceticus complex in intensive care units of the national referral hospital in Jakarta, Indonesia. *Antimicrob. Resist. Infect. Control* 7: 5. doi:10.1186/s13756-017-0296-7
- Schmiel, D.H., & Miller, V.L., 1999. Bacterial phospholipases and pathogenesis. *Microbes Infect.* doi:10.1016/S1286-4579(99)00205-1
- Sebeny, P.J., Riddle, M.S., & Petersen, K., 2008. *Acinetobacter baumannii* skin and soft-tissue infection associated with war trauma. *Clin. Infect. Dis.* 47: 444–449. doi:10.1086/590568
- Segal, H., Garny, S., & Elisha, B.G., 2005. Is ISABA-1 customized for *Acinetobacter*? *FEMS Microbiol. Lett.* 243: 425–429. doi:10.1016/j.femsle.2005.01.005
- Sheng, W.H., Liao, C.H., Lauderdale, T.L., Ko, W.C., Chen, Y.S., Liu, J.W., et al., 2010a. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant *Acinetobacter baumannii*. *Int. J. Infect. Dis.* 14. doi:10.1016/j.ijid.2010.02.2254
- Sheng, W.H., Liao, C.H., Lauderdale, T.L., Ko, W.C., Chen, Y.S., Liu, J.W., et al., 2010b. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant *Acinetobacter baumannii*. *Int. J. Infect. Dis.* 14. doi:10.1016/j.ijid.2010.02.2254
- Sheng, W.H., Liao, C.H., Lauderdale, T.L., Ko, W.C., Chen, Y.S., Liu, J.W., et al., 2010c. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant *Acinetobacter baumannii*. *Int. J. Infect. Dis.* 14. doi:10.1016/j.ijid.2010.02.2254
- Shih, M.J., Lee, N.Y., Lee, H.C., Chang, C.M., Wu, C.J., Chen, P.L., et al., 2008. Risk factors of multidrug resistance in nosocomial bacteremia due to *Acinetobacter baumannii*: A case-control study. *J. Microbiol. Immunol. Infect.* 41: 118–123.
- Shlaes, D.M., & Bradford, P.A., 2018. Antibiotics—From There to Where? *Pathog. Immun.* 3: 19. doi:10.20411/pai.v3i1.231
- Smolyakov, R., Borer, A., Riesenber, K., Schlaeffer, F., Alkan, M., Porath, A., et al., 2003. Nosocomial multi-drug resistant *Acinetobacter baumannii* bloodstream infection: Risk factors and outcome with ampicillin-sulbactam treatment. *J. Hosp. Infect.* 54: 32–38. doi:10.1016/S0195-6701(03)00046-X
- Snitkin, E.S., Zelazny, A.M., Thomas, P.J., Stock, F., Henderson, D.K., Palmore, T.N., et al., 2012. Tracking a hospital outbreak of carbapenem-resistant *Klebsiella pneumoniae* with whole-genome sequencing. *Sci. Transl. Med.* 4. doi:10.1126/scitranslmed.3004129
- Spence, R.P., Towner, K.J., Henwood, C.J., James, D., Woodford, N., & Livermore, D.M., 2002. Population structure and antibiotic resistance of *Acinetobacter* DNA group 2 and 13TU isolates from hospitals in the UK. *J. Med. Microbiol.* 51: 1107–1112. doi:10.1099/0022-1317-51-12-1107
- Stahl, J., Bergmann, H., Göttig, S., Ebersberger, I., & Averhoff, B., 2015.

- Acinetobacter baumannii* Virulence Is Mediated by the Concerted Action of Three Phospholipases D. *PLoS One* 10: e0138360. doi:10.1371/journal.pone.0138360
- Sugawara, E., & Nikaido, H., 2012. OmpA is the principal nonspecific slow porin of *Acinetobacter baumannii*. *J. Bacteriol.* 194: 4089–4096. doi:10.1128/JB.00435-12
- Sultan, A.M., & Seliem, W.A., 2018b. Identifying risk factors for healthcare-associated infections caused by carbapenem-resistant *Acinetobacter baumannii* in a neonatal intensive care unit. *Sultan Qaboos Univ. Med. J.* 18: e75–e80. doi:10.18295/squmj.2018.18.01.012
- Sunenshine, R.H., Wright, M.O., Maragakis, L.L., Harris, A.D., Song, X., Hebden, J., et al., 2007. Multidrug-resistant *Acinetobacter* infection mortality rate and length of hospitalization. *Emerg. Infect. Dis.* 13: 97–103. doi:10.3201/eid1301.060716
- Sydnor, E.R.M., & Perl, T.M., 2011. Hospital epidemiology and infection control in acute-care settings. *Clin. Microbiol. Rev.* 24: 141–173. doi:10.1128/CMR.00027-10
- Tadesse, B.T., Ashley, E.A., Ongarello, S., Havumaki, J., Wijegoonewardena, M., González, I.J., et al., 2017. Antimicrobial resistance in Africa: A systematic review. *BMC Infect. Dis.* 17. doi:10.1186/s12879-017-2713-1
- Thomson, J.M., & Bonomo, R.A., 2005. The threat of antibiotic resistance in Gram-negative pathogenic bacteria:  $\beta$ -lactams in peril! *Curr. Opin. Microbiol.* doi:10.1016/j.mib.2005.08.014
- Tipton, K.A., Dimitrova, D., & Rather, P.N., 2015. Phase-variable control of multiple phenotypes in *Acinetobacter baumannii* strain AB5075. *J. Bacteriol.* 197: 2593–2599. doi:10.1128/JB.00188-15
- Villalón, P., Valdezate, S., Medina-Pascual, M.J., Carrasco, G., Vindel, A., & Saez-Nieto, J.A., 2013. Epidemiology of the acinetobacter-derived cephalosporinase, carbapenem-hydrolysing oxacillinase and metallo- $\beta$ -lactamase genes, and of common insertion sequences, in epidemic clones of *Acinetobacter baumannii* from Spain. *J. Antimicrob. Chemother.* 68: 550–553. doi:10.1093/jac/dks448
- Wallace, L., Daugherty, S.C., Nagaraj, S., Johnson, J.K., Harris, A.D., & Rasko, D.A., 2016. Use of comparative genomics to characterize the diversity of *Acinetobacter baumannii* surveillance isolates in a health care institution. *Antimicrob. Agents Chemother.* 60: 5933–5941. doi:10.1128/AAC.00477-16
- Wang, X., & Qin, L.-J., 2019. A review on *Acinetobacter baumannii*. *J. Acute Dis.* 8. doi:10.4103/2221-6189.250373
- Wisplinghoff, H., Edmond, M.B., Pfaller, M.A., Jones, R.N., Wenzel, R.P., & Seifert, H., 2000. Nosocomial bloodstream infections caused by *Acinetobacter* species in United States hospitals: Clinical features, molecular epidemiology, and antimicrobial susceptibility. *Clin. Infect. Dis.* 31: 690–697. doi:10.1086/314040
- Xu, C., Bilya, S.R., & Xu, W., 2019. adeABC efflux gene in *Acinetobacter baumannii*. *New Microbes New Infect.* 30. doi:10.1016/j.nmni.2019.100549
- Ye, J.J., Huang, C.T., Shie, S. Sen, Huang, P.Y., Su, L.H., Chiu, C.H., et al., 2010. Multidrug resistant *Acinetobacter baumannii*: Risk factors for appearance of



imipenem resistant strains on patients formerly with susceptible strains. *PLoS One* 5. doi:10.1371/journal.pone.0009947

Yoon, E.J., Chabane, Y.N., Goussard, S., Snesrud, E., Courvalin, P., Dé, E., et al., 2015. Contribution of resistance-nodulation-cell division efflux systems to antibiotic resistance and biofilm formation in *Acinetobacter baumannii*. *MBio* 6. doi:10.1128/mBio.00309-15

Zhou, Q., Lee, S.K., Jiang, S.Y., Chen, C., Kamaluddeen, M., Hu, X.J., et al., 2013. Efficacy of an infection control program in reducing ventilator-associated pneumonia in a Chinese neonatal intensive care unit. *Am. J. Infect. Control* 41: 1059–1064. doi:10.1016/j.ajic.2013.06.007



UNIVERSITAS  
GADJAH MADA

**Faktor Risiko yang Mempengaruhi Infeksi *Acinetobacter baumannii* Resisten Terhadap Karbapenem**  
SHIRLEY, Dr. dr. Osman Sianipar DMM, M.Sc., Sp.PK (K).; Dr. dr. Siti Muchayat P. Ms., Sp.PK (K)

Universitas Gadjah Mada, 2020 | Diunduh dari <http://etd.repository.ugm.ac.id/>